Padrão de expressão e significado prognóstico dos genes BCL2, BCL6, CCND2, FN1, LMO2 e SCYA3 pela técnica de PCR em tempo real com linfoma difuso de grandes células B tratado com rituximabe

Xavier, Flávia Caló Aquino

doi:10.11606/t.5.2013.tde-24062013-114437

Cited by 2 publications

(8 citation statements)

References 62 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Together, departments, resources and physical structure are responsible for our positive results: a 3-year overall survival of 82.8% (Figure 2) and a progression-free survival of 87.5% (7). …”

Section: Discussionmentioning

confidence: 86%

“…The complete response rate was 82.5%, and the 3-year overall survival and progression-free survival were 82.8% ( Figure 2 ) and 87.5%, respectively ( 7 ). In the univariate analysis, an interval from signs or symptoms to the beginning of treatment that exceeded 6 months was associated with inferior progression-free survival in 3 years (76.2% vs .…”

Section: Resultsmentioning

confidence: 99%

“…The time from the first sign or symptom to the start of treatment (TST) ranged from 2.17 to 29.4 months, with a mean of 9.3 months and a median of 6.4 months ( Figure 1 ) ( 7 ).…”

Section: Resultsmentioning

confidence: 99%

“…The condition is characterized by rapidly enlarging tumor masses, and 46% of patients present at advanced stages ( 6 ). We have recently demonstrated that this percentage can be as high as 61.9% in our department ( 7 ), possibly due to the difficulty in gaining access to a specialist in Brazil's health system network (SUS).…”

Section: Introductionmentioning

confidence: 96%

See 3 more Smart Citations

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo

Xavier¹,

Levy²,

Pereira³

2014

Clinics

View full text Add to dashboard Cite

OBJECTIVE:Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for nearly 50% of the cases in the Hematology Department of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo. The treatment outcome is influenced by age, abnormal lactate dehydrogenase levels, extranodal infiltration, the disease stage and the patient's performance status. In this study, we sought to report the time-to-treatment of diffuse large B-cell lymphoma in São Paulo's public health system network and its impact on patient outcomes.METHODS:We prospectively followed a cohort of 42 consecutive patients with de novo diffuse large B-cell lymphoma between 2008 and 2012.RESULTS:Our patients had more advanced disease than that reported in the literature (61.9% vs. 46%). In São Paulo's public health system network, it took an average of 7.4 months for a diagnosis to be made and an additional 1.4 months to obtain an appointment with a specialist. Once at our Hematology Department, it took less than 20 days for staging, confirmation of the diagnosis and treatment initiation. An interval from signs or symptoms to treatment of more than 6 months was associated with inferior progression-free survival in 3 years (p = 0.049).CONCLUSION:A delay in the diagnosis of diffuse large B-cell lymphoma is a public health problem and may be associated with worse progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Resultsmentioning

confidence: 99%

“…The time from the first sign or symptom to the start of treatment (TST) ranged from 2.17 to 29.4 months, with a mean of 9.3 months and a median of 6.4 months ( Figure 1 ) ( 7 ).…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo

Xavier¹,

Levy²,

Pereira³

2014

Clinics

View full text Add to dashboard Cite

show abstract

“…Apesar da incidência e importância do LDGCB, que em nossa instituição corresponde a 49,5% de todos os LNH (Gouveia et al, 2011a), há poucas publicações com dados epidemiológicos para a população brasileira (Hallack Neto et al, 2006;Mota, 2006;Hallack Neto, 2007;Marcelino, 2009;Xavier, 2013 (Mota, 2006;Hallack Neto, 2007;WHO, 2008;Hunt e Reicherd, 2008). O mesmo foi observado em relação ao acometimento de SNC.…”

Section: 53-sobrevida Livre De Progressão (Slp)unclassified

Detecção da expressão dos genes associados à resistência múltipla à droga, OCT1 e MDR1 e do gene BCL2 em linfoma difuso de grandes células B\"

Gouveia¹

View full text Add to dashboard Cite

Padrão de expressão e significado prognóstico dos genes BCL2, BCL6, CCND2, FN1, LMO2 e SCYA3 pela técnica de PCR em tempo real com linfoma difuso de grandes células B tratado com rituximabe

Cited by 2 publications

References 62 publications

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo

Detecção da expressão dos genes associados à resistência múltipla à droga, OCT1 e MDR1 e do gene BCL2 em linfoma difuso de grandes células B\"

Contact Info

Product

Resources

About